Latest Articles and Analysis

Congress has introduced the most ambitious federal hepatitis C elimination bill in a generation — $9.8 billion, no cost-sharing, and a delivery investment long overdue. The procurement model at its center could undermine the access it promises.

Prescription Drug Affordability Boards are operating in states across the country, but their primary tool — Upper Payment Limits — threatens pharmacies, Medicaid programs, and the patients they're supposed to help. The evidence is mounting that UPLs are the wrong solution to a real problem.

More than half of people living with HIV in the U.S. are now 50 or older—a public health success that demands more than good referral networks. Building HIV-inclusive aging organizations means developing real capacity before someone ever needs to be sent somewhere else.

A new Senate bill would require 340B hospitals to document where their savings go and, for the first time, mandate direct discounts for low-income patients at the pharmacy counter. Here's what the proposal contains and why the stakes are high for the communities 340B was built to serve.

For the first time, a finite course of therapy has produced a functional cure for chronic hepatitis B in large-scale phase 3 trials, but the communities carrying the heaviest burden of this disease are also the least likely to be screened, diagnosed, or insured. Whether this milestone translates into population-level progress is a policy question, not a scientific one.

Nearly a year after shutting down the 988 Lifeline's LGBTQ+ youth specialized services, the administration says Press 3 will return by the end of 2026, restored under an executive order that refuses to recognize some of the young people it exists to serve. The research record shows what that costs: harm to mental health, disrupted HIV care engagement, and advocate burnout. This Pride, taking care of ourselves so we can take care of each other is a public health strategy.

A proposed OMB rule would let political appointees veto or cancel federal research grants, dismantling the peer-review system and targeting the disparate-impact analysis that maps where HIV concentrates and why. For people living with HIV, that research is the foundation of Ending the HIV Epidemic. The comment period closes July 13.

On April 24, 2026, a nurse in Ituri Province in the Democratic Republic of the Congo (DRC) developed a fever. She died three days later. Her samples were tested locally and returned negative, because...

On April 24, 2026, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued a Dear Colleague letter that withdraws federal funding eligibility from fentanyl test strips, sterile...

For a long time, I thought advocacy meant surviving the next appointment. I thought it meant learning how to explain my pain better, how to prepare for another referral visit, how to justify why I...

Editor's Note: This article was originally published on April 10, 2026, by Lupus Colorado and is republished here with permission. The Patient Affordability Roundtable discussed in this piece was...

On April 1, Taylor Swift dropped a surprise music video for her song "Elizabeth Taylor," directing streaming royalties to the Elizabeth Taylor AIDS Foundation (ETAF). Two weeks earlier, on March 18,...

Public health programs like 340B are designed with a clear and urgent purpose: to improve community health, expand access to care, and protect the most vulnerable among us. Whether it’s ensuring...

Rising employer premiums averaging 9.5% erode wages, forcing workers to delay care.

CROI 2026 showcased breakthroughs alongside funding crisis disrupting global and domestic HIV services.

ADAPs achieve 87% viral suppression but face funding crisis as multiple policies erode 340B rebates.

Break Up Big Medicine Act would force structural separation of insurers, PBMs, and pharmacies.

Medicare drug negotiation's third wave includes Biktarvy, raising HIV treatment access concerns.

Administration expands OUD medication access while defunding SAMHSA and restricting harm reduction.

FY2026 preserves HIV funding but level funding can't support long-acting therapeutics or growing needs.